Novo Nordisk A/S (NYSE:NVO) closed Wednesday’s trading session at $49.16 days after a slight stock price fall following the announcement that it filed for Fiasp’s label update with the Food and Drug Administration (FDA) and the European Medicines Agency E(MA).
The company announced the news about the filing on March 1 revealing that it made the filing with the two regulatory authorities seeking authorization to use Fiasp in adolescents and children. Novo Nordisk filed for the label update with the FDA and the EMA with the goal of using the treatment as mealtime insulin for children and adolescents that have type 1 diabetes. Fiasp is currently approved as a treatment for adult patients living with diabetes.
“Clinical experience shows that for conventional rapid-acting insulins to work best, they need to be administered ahead of the meal, which might require a lot of guesswork,” stated Novo Nordisk’s executive Vice President Mads Krogsgaard Thomsen.
Thomsen also added that Fiasp is unique because it features a rapid-acting action profile which is better than the traditional insulin aspart. Diabetes patients can administer the Novo Nordisk insulin just before a meal and this helps to eliminate the guesswork that patients usually go through during mealtime. The biopharma submitted the Fiasp filing based on the data observed in the onset seven trial. The latter evaluated the treatment’s safety and efficacy profile in children and adolescents with type 1 diabetes.
Novo Nordisk strikes partnership with Health2Sync for digital diabetes management in Japan
Novo Nordisk recently announced a collaboration with Health2Sync through which they will work towards digital management of diabetes. The move will also facilitate digital communication between diabetics and healthcare providers.
Health2Sync eliminates the need for doctor visits by providing a digital option through which healthcare providers can stay in touch and monitor diabetes patients. The Health2Sync app provides nudges and hints pertaining to important things like blood glucose management, exercise, and meals. These hints allow patients to manage their treatment plans easily. Novo Nordisk’s Vice President John Dawber stated that his company and Health2Sync have the same goal of improving the lives of people suffering from diabetes.